J Korean Diabetes.  2015 Jun;16(2):123-129. 10.4093/jkd.2015.16.2.123.

New Technology for Type 1 Diabetes

• Yang Y
• Cho JH

• KMID: 2137270
• DOI: http://doi.org/10.4093/jkd.2015.16.2.123

Abstract

Type 1 diabetes is an autoimmune disease with insulin deficiency which causes microvascular complications such as retinopathy, nephropathy and neuropathy. There have been some trials to simulate the pancreatic endocrine function of insulin and glucagon for homeostatic equilibration of blood glucose, developing artificial pancreas. There are three major functional components of the modern artificial pancreas, a continuous glucose-monitoring system, an insulin-infusion pump and a control algorithm. There are commercially available continuous glucose monitoring systems with subcutaneous glucose measuring, however, there have been many attempts to develop more efficient glucose monitoring systems, including noninvasive systems. Thanks to technological advances and the miniaturization of electronics, recent advances in the accuracy and performance of these systems have placed research on the threshold of prototype commercial devices and large-scale outpatient feasibility studies. In addition, smartphone technology has created the opportunity for caregivers to receive push notification alerts and makes it possible to provide patients with advisory or decision-support systems. Even though there are still some remaining challenges to develop a successful artificial pancreas, glucose control in type 1 diabetes will be more efficient with its advent.

Keyword

Artificial pancreas; Continuous glucose-monitoring system; New technology; Non-invasive; Type 1 diabetes

MeSH Terms

Autoimmune Diseases
Blood Glucose
Caregivers
Glucagon
Glucose
Humans
Insulin
Miniaturization
Outpatients
Pancreas, Artificial
Blood Glucose
Glucagon
Glucose
Insulin

Reference

References

1. Cryer PE. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes. 1994; 43:1378–89.

2. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W. An artificial endocrine pancreas. Diabetes. 1974; 23:389–96.

3. Greenbaum CJ, Schatz DA, Haller MJ, Sanda S. Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes. Diabetes. 2012; 61:1323–30.

4. Michels AW, Eisenbarth GS. Immune intervention in type 1 diabetes. Semin Immunol. 2011; 23:214–9.

5. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013; 309:2473–9.

6. S⊘rensen JS, Johannesen J, Pociot F, Kristensen K, Thomsen J, Hertel NT, Kjaersgaard P, Brorsson C, Birkebaek NH. Danish Society for Diabetes in Childhood and Adolescence. Residual β-Cell function 3–6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care. 2013; 36:3454–9.

7. Zhang B, Kumar RB, Dai H, Feldman BJ. A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes. Nat Med. 2014; 20:948–53.

8. Ziegler R, Heidtmann B, Hilgard D, Hofer S, Rosenbauer J, Holl R. DPV-Wiss-Initiative. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2011; 12:11–7.

9. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008; 359:1464–76.

10. Wong JC, Foster NC, Maahs DM, Raghinaru D, Bergenstal RM, Ahmann AJ, Peters AL, Bode BW, Aleppo G, Hirsch IB, Kleis L, Chase HP, DuBose SN, Miller KM, Beck RW, Adi S. T1D Exchange Clinic Network. Realtime continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care. 2014; 37:2702–9.

11. Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, Wilson LM, Haberl EB, Brick J, Bass EB, Golden SH. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and metaanalysis. Ann Intern Med. 2012; 157:336–47.

12. Tura A. Noninvasive glycaemia monitoring: background, traditional findings, and novelties in the recent clinical trials. Curr Opin Clin Nutr Metab Care. 2008; 11:607–12.

13. Diabetes Research in Children Network (DirecNet) Study Group. Accuracy of the GlucoWatch G2 Biographer and the continuous glucose monitoring system during hypoglycemia: experience of the Diabetes Research in Children Network. Diabetes Care. 2004; 27:722–6.

14. Vashist SK. Non-invasive glucose monitoring technology in diabetes management: a review. Anal Chim Acta. 2012; 750:16–27.

15. Farandos NM, Yetisen AK, Monteiro MJ, Lowe CR, Yun SH. Contact lens sensors in ocular diagnostics. Adv Healthc Mater. 2015; 4:792–810.

16. Klueh U, Liu Z, Feldman B, Henning TP, Cho B, Ouyang T, Kreutzer D. Metabolic biofouling of glucose sensors in vivo: role of tissue microhemorrhages. J Diabetes Sci Technol. 2011; 5:583–95.

17. van den Bosch EE, de Bont NH, Qiu J, Gelling OJ. A promising solution to enhance the sensocompatibility of biosensors in continuous glucose monitoring systems. J Diabetes Sci Technol. 2013; 7:455–64.

18. Peyser T, Zisser H, Khan U, Jovanovič L, Bevier W, Romey M, Suri J, Strasma P, Tiaden S, Gamsey S. Use of a novel fluorescent glucose sensor in volunteer subjects with type 1 diabetes mellitus. J Diabetes Sci Technol. 2011; 5:687–93.

19. Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems. Available from:. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm259305.pdf. (updated 2012 Nov 9).

20. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes. 2011; 60:2672–82.

21. Renard E, Cobelli C, Kovatchev BP. Closed loop developments to improve glucose control at home. Diabetes Res Clin Pract. 2013; 102:79–85.

22. Elleri D, Dunger DB, Hovorka R. Closed-loop insulin delivery for treatment of type 1 diabetes. BMC Med. 2011; 9:120.

23. Thabit H, Hovorka R. Closed-loop insulin delivery in type 1 diabetes. Endocrinol Metab Clin North Am. 2012; 41:105–17.

24. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol. 2011; 7:385–95.

25. Kumareswaran K, Evans ML, Hovorka R. Closed-loop insulin delivery: towards improved diabetes care. Discov Med. 2012; 13:159–70.

26. McCall AL, Farhy LS. Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control. Minerva Endocrinol. 2013; 38:145–63.

27. Keith-Hynes P, Guerlain S, Mize B, Hughes-Karvetski C, Khan M, McElwee-Malloy M, Kovatchev BP. DiAs user interface: a patient-centric interface for mobile artificial pancreas systems. J Diabetes Sci Technol. 2013; 7:1416–26.

28. Dassau E, Jovanovic L, Doyle FJ 3rd, Zisser HC. Enhanced 911/global position system wizard: a telemedicine application for the prevention of severe hypoglycemia–monitor, alert, and locate. J Diabetes Sci Technol. 2009; 3:1501–6.

29. Rigla M, Hernando ME, Gómez EJ, Brugués E, García-Sáez G, Torralba V, Prados A, Erdozain L, Vilaverde J, de Leiva A. A telemedicine system that includes a personal assistant improves glycemic control in pump-treated patients with type 1 diabetes. J Diabetes Sci Technol. 2007; 1:505–10.